# Teleflex Announces Second Quarter 2025 Earnings Conference Call Information
Canonical URL: https://biopharmsignal.com/news/TFX/teleflex-announces-second-quarter-2025-earnings-conference-call-information-31740172
Ticker: TFX
Company: Teleflex
Source: Teleflex
Published: 2025-07-17 10:30 EST
## Summary

Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial...

## Article Body
Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 31, 2025.

To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, teleflex.com .

An audio replay of the call will be available beginning at 11:00 am Eastern Time on July 31, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028.

About Teleflex Incorporated

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com .

Contacts: Teleflex Incorporated: Lawrence Keusch Vice President, Investor Relations and Strategy Development
## Recent Company News
- 2026-01-08 11:30 EST — [Teleflex Announces Leadership Transition](https://biopharmsignal.com/news/TFX/teleflex-announces-leadership-transition-d572754c) — Source: Teleflex
- 2025-12-09 14:04 EST — [Teleflex Announces Sale of Acute Care, Interventional Urology, and OEM Businesses for $2.03 Billion](https://biopharmsignal.com/news/TFX/teleflex-announces-sale-of-acute-care-interventional-urology-and-oem-businesses--da92348c) — Source: Teleflex
- 2025-11-14 11:30 EST — [Teleflex to Present at the Jefferies Global Healthcare Conference in London](https://biopharmsignal.com/news/TFX/teleflex-to-present-at-the-jefferies-global-healthcare-conference-in-london-78b44fb9) — Source: Teleflex
- 2025-11-06 11:45 EST — [Teleflex Announces Quarterly Dividend](https://biopharmsignal.com/news/TFX/teleflex-announces-quarterly-dividend-b49b5009) — Source: Teleflex
- 2025-11-06 11:30 EST — [Teleflex Reports Third Quarter Financial Results and Full Year 2025 Outlook](https://biopharmsignal.com/news/TFX/teleflex-reports-third-quarter-financial-results-and-full-year-2025-outlook-7e2975be) — Source: Teleflex
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)